ABG Innovation Capital Partners III GP Ltd Long-Term Concentrated

Name: ABG Innovation Capital Partners III GP Ltd Q1 2021 13F Filing | 13F Explorer
Creator: ABG Innovation Capital Partners III GP Ltd
Published: 2021-05-17

Location: Central, Hong Kong, Hong Kong

CIK: 0001845297 · Show all filings

Period: Q1 2021 (← Previous) (Next →)

Filing Date: May 17, 2021

Total Value: $204M (100.0% shares, 0.0% debt)

Holdings (7)

— ATEA PHARMACEUTICALS INC 80.1%

Value $163M Shares 2,639,178 Est. Cost $61.75 Unrealized —

LUNG PULMONX CORP 18.7%

Value $38.12M Shares 833,333 Est. Cost $48.97 Unrealized +17.1%

GNCAQ GENOCEA BIOSCIENCES INC 0.5%

Value $1.016M Shares 375,000 Est. Cost $2.28 Unrealized +30.0%

— SYNLOGIC INC 0.4%

Value $737K Shares 205,906 Est. Cost $2.16 Unrealized —

— AERPIO PHARMACEUTICALS INC 0.3%

Value $516K Shares 400,000 Est. Cost $0.98 Unrealized —

— NABRIVA THERAPEUTICS PLC 0.0%

Value $76,000 Shares 45,849 Est. Cost $2.42 Unrealized —

— IDERA PHARMACEUTICALS INC 0.0%

Value $73,000 Shares 56,250 Est. Cost $3.66 Unrealized —

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
—	ATEA PHARMACEUTICALS INC	2,639,178	$163M	80.1%	$61.75	—	COM	04653R106
LUNG	PULMONX CORP	833,333	$38.12M	18.7%	$48.97	+17.1%	COM	745848101
GNCAQ	GENOCEA BIOSCIENCES INC	375,000	$1.016M	0.5%	$2.28	+30.0%	COM NEW	372427401
—	SYNLOGIC INC	205,906	$737K	0.4%	$2.16	—	COM	87166L100
—	AERPIO PHARMACEUTICALS INC	400,000	$516K	0.3%	$0.98	—	COM	00810B105
—	NABRIVA THERAPEUTICS PLC	45,849	$76,000	0.0%	$2.42	—	SHS	G63637113
—	IDERA PHARMACEUTICALS INC	56,250	$73,000	0.0%	$3.66	—	COM PAR	45168K405